MET and non-small cell lung carcinoma: Further analyses for patients with MET amplification showed limited efficacy in those with gene copy number < 10 (ORR: 7–12%), but favorable efficacy in those with gene copy number ≥ 10 (ORR: 29% in patients with previously treated NSCLC, and 40% in treatment-naïve patients).